Key facts
- This page summarizes Kufe LLC's Form 3 filing for Hillstream BioPharma Inc. (THAR).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Jan 2022, 15:19.
Kufe LLC - 11 Jan 2022 Form 3 Insider Report for Hillstream BioPharma Inc. (THAR)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- THAR
- Reported as of
- 11 Jan 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Donald Kufe
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Kufe LLC filed Form 3 for Hillstream BioPharma Inc. (THAR) on 13 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HILS
holding
Common stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 810,395
- Date
- 11 Jan 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HILS
holding
Derivative
Convertible Note
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 11 Jan 2022
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On August 10, 2021, the Registrant issued the Reporting Person a $100,000 note which matures on the earlier of (i) August 10, 2024 and (ii) the closing of the Next Equity Financing. The note shall automatically convert into the type of Equity Securities issued in the Next Equity Financing and shall be equal to the quotient obtained by dividing the outstanding amount of the note by the lesser of (i) 80% of the price paid per Equity Security in the Next Equity Financing and (ii) an equity valuation of the Registrant of $50 million. "Next Equity Financing" means the next sale (or series of related sales) by the Registrant of its Equity Securities pursuant to which the Registrant receives gross proceeds of not less than $7.5 million (inclusive of the aggregate amount of debt securities converted into Equity Securities upon conversion or cancellation of notes). "Equity Securities" means, subject to certain exceptions, the Registrant's common stock and common stock equivalents.